Channel Therapeutics Corp

Channel is a biotechnology company developing & commercializing novel, non-opioid, non-addictive therapeutics to alleviate pain & associated conditions $CHRO

[Channel Therapeutics Corp @ChromocellThera]

Channel Therapeutics Announces Positive Efficacy Results for the Treatment of Eye Pain Using its NaV1.7 Inhibitor in Multiple Preclinical In Vivo Models $CHRO

https://t.co/eA7xLRUo79

[Channel Therapeutics Corp @ChromocellThera]

Florida biopharma Ligand Pharmaceuticals (Nasdaq: $LGND) subsidiary Pelthos Therapeutics is to merge with Channel Therapeutics (NYSE American: $CHRO), a developer of non-opioid pain treatments.

The merger will be supported by $50 million in capital raised from a group of strategic investors led by Murchinson.
https://t.co/8UALMKZe0H

[Channel Therapeutics Corp @ChromocellThera]

Ligand Subsidiary Pelthos Therapeutics to Combine with Channel Therapeutics $CHRO $LGND

https://t.co/jsv5F0D4AC

[Channel Therapeutics Corp @ChromocellThera]

It's #PainAwarenessMonth. Did you know one-third of the U.S. population suffers from chronic pain? Chromocell is dedicated to developing innovative, non-addictive treatments to address this unmet need. See our pipeline here: https://t.co/EkyIk7plnw $CHRO

[Channel Therapeutics Corp @ChromocellThera]

#ICYMI - Chromocell CEO Frank Knuettel discussed Chromocell's progress and strategy in pioneering innovative non-opioid pain treatment therapeutics during the @HCWCO 26th Annual Global Investment Conference. Watch a replay of his presentation here: https://t.co/gvld4QUP52 $CHRO

[Channel Therapeutics Corp @ChromocellThera]

September is #PainAwarenessMonth. At Chromocell, we are committed to advancing non-opioid alternatives for pain treatment. Learn more about our innovative clinical programs that are paving the way for safer, more effective solutions: https://t.co/EkyIk7plnw $CHRO

[Channel Therapeutics Corp @ChromocellThera]

Dr. Stephen Waxman, chair of our Scientific Advisory Board, is one of the foremost experts in NaV research. Learn more about our accomplished team of scientific advisors guiding our clinical development: https://t.co/lzeJx0dRWH $CHRO

[Channel Therapeutics Corp @ChromocellThera]

Our management team, board of directors, and scientific advisors are composed of accomplished business leaders, industry-leading experts in pain research and management, and experienced clinical development professionals. Read more about our leadership: https://t.co/7jyha4G1OA $CHRO

[Channel Therapeutics Corp @ChromocellThera]

@HCWCO In addition to the presentation, one-on-one meetings are available to those registered to attend the conference. For more information, reach out directly to your institutional salesperson or visit: https://t.co/kxTpTJZNnR $CHRO

[Channel Therapeutics Corp @ChromocellThera]

Chromocell will be featured as a presenting company at the @HCWCO 26th Annual Global Investment Conference. Frank Knuettel, CEO of Chromocell, will provide a corporate overview during the presentation. For more information: https://t.co/F5HQ6GVXBK $CHRO

[Channel Therapeutics Corp @ChromocellThera]

Don't miss an update. Get the latest Chromocell company press releases, filings and special announcements by signing up for email alerts: https://t.co/JqYkIIjzg0 $CHRO

[Channel Therapeutics Corp @ChromocellThera]

Small fiber neuropathy may begin with mild discomfort, but the pain can often become debilitating and affect quality of life. New treatments are needed to help those suffering from small fiber neuropathy. Learn more about the condition here: https://t.co/lEa81wbbut $CHRO

[Channel Therapeutics Corp @ChromocellThera]

Chromocell has launched a share repurchase plan as we continue to develop groundbreaking treatments for neuropathic and chronic #pain. Find out more. https://t.co/GjpZ28QmyI $CHRO

[Channel Therapeutics Corp @ChromocellThera]

Focused on enhancing shareholder value, Chromocell has introduced a $250,000 stock repurchase plan while continuing to drive innovation in non-opioid pain treatments. Stay tuned for upcoming updates on our drug development efforts. https://t.co/GjpZ28QmyI $CHRO

[Channel Therapeutics Corp @ChromocellThera]

Chromocell Chief Executive Officer and President, Frank Knuettel, comments on the recent announcement of the Company's stock repurchase plan. Learn more here: https://t.co/GjpZ28QmyI $CHRO

[Channel Therapeutics Corp @ChromocellThera]

Chromocell's Board has authorized a stock repurchase plan, citing current stock price as an attractive investment, which we believe may enhance shareholder value. We remain committed to advancing our pipeline of neuropathic & chronic pain treatments. https://t.co/GjpZ28QmyI $CHRO

[Channel Therapeutics Corp @ChromocellThera]

Chromocell has announced a stock repurchase plan of up to $250,000, representing ~23% of the non-affiliate float. This move reflects confidence in the company’s ongoing progress in non-opioid pain therapeutics. https://t.co/GjpZ28QmyI $CHRO

[Channel Therapeutics Corp @ChromocellThera]

Chromocell Announces Stock Repurchase Plan: https://t.co/GjpZ28QmyI $CHRO

[Channel Therapeutics Corp @ChromocellThera]

CC8464 has potential to provide pain relief for patients suffering from erythromelalgia and idiopathic small fiber neuropathy (iSFN). Find out more about our lead drug candidate which received fast-track status from the FDA. https://t.co/EkyIk7plnw $CHRO

[Channel Therapeutics Corp @ChromocellThera]

Our NaV1.7 sodium channel blockers are designed to modulate pain signals to provide analgesic effects without activating central nervous system receptors and therefore displaying no addictive properties. https://t.co/EkyIk7plnw $CHRO